Balanced amino acid supplement for Liver Cirrhosis

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Liver CirrhosisBalanced amino acid supplement (BAA) - DietarySupplement
Eligibility
18 - 70
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether leucine will help increase muscle mass in people with cirrhosis, by looking at the response to leucine in cirrhotic patients compared to a control group. They will measure this by looking at the rate of protein synthesis in muscle, and how this changes in response to leucine.

Eligible Conditions
  • Liver Cirrhosis

Treatment Effectiveness

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: Baseline to 90 days

Baseline to 90 days
Compare Fractional Synthesis Rate

Trial Safety

Trial Design

2 Treatment Groups

Balanced amino acid supplement
1 of 2
Leucine enriched essential amino acid
1 of 2

Active Control

32 Total Participants · 2 Treatment Groups

Primary Treatment: Balanced amino acid supplement · No Placebo Group · N/A

Balanced amino acid supplement
DietarySupplement
ActiveComparator Group · 1 Intervention: Balanced amino acid supplement (BAA) · Intervention Types: DietarySupplement
Leucine enriched essential amino acid
DietarySupplement
ActiveComparator Group · 1 Intervention: Leucine enriched essential amino acid (EEA/LEU) · Intervention Types: DietarySupplement

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline to 90 days

Who is running the clinical trial?

The Cleveland ClinicLead Sponsor
949 Previous Clinical Trials
1,409,720 Total Patients Enrolled
6 Trials studying Liver Cirrhosis
223 Patients Enrolled for Liver Cirrhosis

Eligibility Criteria

Age 18 - 70 · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: